| 引用本文:周璇1，周大勇1，洪峰1，王玉玉1，刘颖1，段吉瑞1，姚舒雅2，任文静2.血必净注射液联合西医治疗重症急性胰腺炎的Meta分析[J].世界中医药,2022,(19):. |
|
| 血必净注射液联合西医治疗重症急性胰腺炎的Meta分析 |
| Meta-analysis of Xuebijing Injection Combined with Western Medicine in the Treatment of Severe Acute Pancreatitis |
| 投稿时间：2020-12-23 |
| DOI：10.3969/j.issn.1673-7202.2022.19.014 |
| 中文关键词: 重症急性胰腺炎 血必净 西医治疗 Meta分析 随机对照试验 临床疗效 |
| English Keywords:Severe acute pancreatitis Xuebijing Western medicine treatment Meta-analysis Randomized controlled trials Clinical curative effect |
| 基金项目:安徽省科技厅面上攻关项目（202004a07020014） |
|
| 摘要点击次数: 491 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的：系统评价应用血必净注射液联合西医治疗重症急性胰腺炎的临床疗效。方法：计算机检索国家知识基础设施数据库（CNKI）、中国学术期刊数据库（CSPD）、中文科技期刊数据库（CCD）、中国生物医学文献（CBM）、The Cochrane Library、EMbase和PubMed数据库，收集建库至2020年11月血必净注射液联合西医治疗重症急性胰腺炎的临床随机对照试验文献，依据纳入和排除标准筛选文献后采用Revman5.4软件进行评价。结果：最终纳入19项研究，共1402例患者，其中血必净注射液联合西医观察组698例，对照组704例。与对照组比较，观察组血淀粉酶和炎症指标：血淀粉酶（MD=-135.59，95%CI为-179.34~-91.84，P<0.001）、肿瘤坏死因子-α（MD=-34.03,95%CI为-45.09~-22.98，P<0.001）、超敏C反应蛋白(MD=-19.40,95%CI为-23.33~-15.48，P<0.001)、白细胞介素-6(MD=-17.26,95%CI为-22.76~-11.75,P<0.001)、白细胞计数（MD=-3.55，95%CI为-4.63~-2.48,P<0.001）均明显下降；有效率高于对照组（RR=1.22,95%CI为1.15~1.29，P<0.001）。观察组胃肠功能恢复时间（MD=-1.87，95%CI为-2.44~-1.29，P<0.001）、腹痛腹胀恢复时间（MD=-1.95,95%CI为-2.53~-1.36，P<0.001）、血淀粉酶恢复时间（MD=-2.03，95%CI为-3.78~-0.28，P<0.001）与对照组比较均明显缩短。结论：应用血必净注射液联合西医治疗重症急性胰腺炎可进一步改善患者的血淀粉酶及炎症指标，血淀粉酶、胃肠功能、腹痛腹胀恢复时间明显缩短，患者临床有效率明显提高。但是，由于所纳入研究的质量较差，上述结论仍需要通过高质量的随机对照试验来证明。 |
| English Summary: |
| To systematically evaluate the clinical effect of Xuebijing Injection combined with western medicine on the treatment of severe acute pancreatitis.Methods:China National Knowledge Infrastructure(CNKI)，VIP Chinese Technology Periodical Database(VIP)，Wanfang Data，China Biology Medicine disc(CBMdisc)，Cochrane Library，Embase，and PubMed were retrieved to collect clinical randomized controlled trials of Xuebijing injection combined with western medicine in the treatment of severe acute pancreatitis.The retrieval time was from the establishment of the database to November 2020.Literature was screened out according to inclusion and exclusion criteria and evaluated by RevMan 5.4.Results:A total of 1402 patients were included in 19 studies，including 698 cases in the Xuebijing Injection combined with western medicine treatment group and 704 cases in the control group.As compared with the control group，blood amylase and inflammation indexes in the treatment group including blood amylase(MD=-135.59，95%CI -179.34 to -91.84，P<0.001)，tumor necrosis factor-α(MD=-34.03，95%CI -45.09 to -22.98，P<0.001)，hypersensitive C-reactive protein(MD=-19.40，95%CI -23.33 to -15.48，P<0.001)，interleukin-6 MD=-17.26 to 95%CI -22.76 to -11.75，P<0.001)，and white blood cell count(MD=-3.55，95%CI -4.63 to -2.48，P<0.001) were significantly decreased.The effective rate of the treatment group was higher than that of the control group(RR=1.22，95%CI 1.15 to 1.29，P<0.001).The recovery time of gastrointestinal function(MD=-1.87，95%CI -2.44 to -1.29，P<0.001)，the recovery time of abdominal pain and abdominal distend(MD=-1.95，95%CI -2.53 to -1.36，P<0.001)，and the recovery time of blood amylase(MD=-2.03，95%CI -3.78 to -0.28，P<0.001) of the treatment group were shortened as compared with the control group.Conclusion:Xuebijing Injection combined with western medicine in the treatment of severe acute pancreatitis can further improve the blood amylase and inflammation indexes，significantly shorten the recovery time of blood amylase，gastrointestinal function，abdominal pain，and abdominal distend，and improve the clinical efficiency of patients.However，due to the poor quality of the included studies，these conclusions still need to be confirmed by high-quality randomized controlled trials. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
